Search

ROCKVILLE: MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, [...]

London: MaxCyte Inc has issued the following press release: MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing 'next-generation cell therapeutics' - Inks strategic platform license agreement [...]

M2 PHARMA-May 22, 2024-MaxCyte and Legend Biotech sign strategic platform licence agreement (C)2024 M2 COMMUNICATIONS MaxCyte Inc (Nasdaq: MXCT) (LSE: MXCT), a cell-engineering company, announced on Wednesday that it has [...]

M2 EQUITYBITES-May 22, 2024-MaxCyte and Legend Biotech sign strategic platform licence agreement (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk MaxCyte Inc (Nasdaq: MXCT) (LSE: MXCT), a cell-engineering company, announced on Wednesday that it [...]

ROCKVILLE: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing [...]

ROCKVILLE: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing [...]

M2 PHARMA-January 23, 2024-MaxCyte and Imugene sign strategic platform license to propel cancer immunotherapy programs (C)2024 M2 COMMUNICATIONS Cell engineering company MaxCyte Inc (Nasdaq: MXCT; LSE: MXCT) and Imugene (ASX: [...]

M2 EQUITYBITES-January 23, 2024-MaxCyte and Imugene sign strategic platform license to propel cancer immunotherapy programs (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Cell engineering company MaxCyte Inc (Nasdaq: MXCT; LSE: MXCT) and Imugene [...]

ROCKVILLE: MaxCyte, Inc has issued the following news release: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

ROCKVILLE, Md: MaxCyte, Inc has issued the following news release: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development [...]

London: MaxCyte Inc has issued the following press release: MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish [...]

ROCKVILLE: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support [...]

ROCKVILLE: MaxCyte, Inc has issued the following news release: MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

Vertex Pharmaceuticals will continue to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform to support gene-edited cell therapy exa-cel, formerly known as CTX001(TM) for hemoglobinopathies ROCKVILLE, Md., Sept. 28, 2022 [...]

2023 JAN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling [...]

GAITHERSBURG: MaxCyte, Inc has issued the following news release: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the [...]

NEW YORK and GAITHERSBURG, Md., Feb 01, 2022 (GLOBE NEWSWIRE via COMTEX) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell [...]

SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct 28, 2021 (GLOBE NEWSWIRE via COMTEX) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo [...]

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Nkarta, [...]

GAITHERSBURG: Maxcyte, Inc. has issued the following news release: MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical [...]

Agreement represents MaxCyte's 14th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation technology and ExPERT(TM) platform in conjunction with the development of its hypoimmune cell therapy programs GAITHERSBURG, [...]

MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), [...]

FLORHAM PARK: MaxCyte, Inc. has issued the following news release: Celularity, Inc. ('Celularity'), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic [...]

Celularity to utilize MaxCyte's Flow Electroporation technology and ExPERT(TM) platform to advance its off-the-shelf placental-derived allogeneic cellular therapies to treat hematological malignancies, solid tumors, and infectious and degenerative diseases FLORHAM [...]

London: London Stock Exchange plc has issued the following announcement: Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, and MaxCyte, Inc., (LSE: MXCT, MXCL), a [...]

Myeloid to utilize MaxCyte's Flow Electroporation technology and ExPERT(TM) platform to advance its novel cell therapies to treat solid tumors, T cell lymphoma and glioblastoma CAMBRIDGE, Mass. and GAITHERSBURG, Md., [...]

London: MaxCyte Inc has issued the following press release: MaxCyte Inc - cell and gene therapies - Signs clinical and commercial licensing agreement with Apeiron Biologics AG. Apeiron to obtain [...]

VIENNA and GAITHERSBURG: MaxCyte, Inc. has issued the following news release: APEIRON Biologics AG ('APEIRON'), a private biotechnology company specializing in the discovery, development and commercialization of novel immunotherapies for [...]

APEIRON Biologics AG ('APEIRON'), a private biotechnology company specializing in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases, and MaxCyte, Inc., (LSE: MXCT, MXCL), a [...]

Viennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcytes electroporation platform for APN401 development. Under the agreement, APEIRON Biologics AG (Vienna) gets the [...]

London: London Stock Exchange plc has issued the following announcement: Caribou Biosciences, Inc. ('Caribou'), a leading CRISPR genome editing company, and MaxCyte, Inc., (LSE: MXCT), a global cell-based therapies and [...]

- Agreement enables Caribou to utilize MaxCyte's ExPERT platform for its CRISPR gene-edited, allogeneic T cell therapy programs BERKELEY, Calif. and GAITHERSBURG, Md., May 7, 2020 /PRNewswire/ -- Caribou Biosciences, [...]

London: London Stock Exchange plc has issued the following announcement: MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement * Agreement enables Allogene, a pioneer in the development of [...]

GAITHERSBURG: MaxCyte, Inc. has issued the following press release: MaxCyte, Inc., a global cell-based therapies and life sciences company, and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering [...]

- Agreement enables Allogene, a pioneer in the development of AlloCAR T(TM) therapies for cancer, to utilize MaxCyte's ExPERT(TM) platform in target candidates GAITHERSBURG, Md. and SOUTH SAN FRANCISCO, Calif., [...]

2021 JAN 25 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, [...]

London: London Stock Exchange plc has issued the following announcement: Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer - [...]

London: MaxCyte Inc has issued the following press release: MaxCyte Inc on Thursday said it has signed a clinical and commercial license agreement with oncology business Vor Biopharma. Under the [...]

CAMBRIDGE, Mass: Vor Biopharma has issued the following press release: Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a [...]

- Clinical and commercial agreement using MaxCyte's recently launched ExPERT[TM] platform enables up to five of Vor's engineered cell therapies and includes development and approval milestones and sales-based payments - [...]

Editas Medicine, Inc. a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine [...]

London: MaxCyte Inc has issued the following press release: Cell-based therapy and life sciences firm MaxCyte Inc and Editas Medicine Inc on Monday unveiled a new licence agreement covering development [...]

CAMBRIDGE: Editas Medicine, Inc. has issued the following press release: Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences [...]

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies [...]

Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS genome-editing technology DURHAM, N.C. and GAITHERSBURG, Md., Nov. 14, 2018 /PRNewswire/ -- [...]

London: MaxCyte, Inc. has issued the following news release: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of [...]

BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Mar 14, 2017 (GLOBE NEWSWIRE via COMTEX) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and [...]

MaxCyte Inc., of Gaithersburg, Md., said Yokohama, Japan-based Medinet Co. Ltd. signed an exclusive license, developing and supply agreement to use MaxCyte's cell loading system to support clinical studies and [...]